Answer
Capivasertib potently and selectively inhibits the kinase activity of all three AKT isoforms (AKT1, AKT2 and AKT3), inhibiting phosphorylation of AKT substrates involved in cellular survival, proliferation and other processes.
Sources for this answer
- Truqap 160 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 5Document updated
Sources checked